镓-68前列腺特异性膜抗原PET/CT与2-[18F]氟-2-脱氧-D-葡萄糖PET/CT检测甲状腺癌病灶的价值:前瞻性头对头比较
该前瞻性头对头研究纳入23例分化型甲状腺癌(DTC)和17例放射性碘难治性分化型甲状腺癌(RAIR-DTC)患者,比较[68Ga]Ga-PSMA-11 PET/CT与2-[18F]FDG PET/CT的病灶检出率。结果显示[68Ga]Ga-PSMA-11 PET/CT在DTC和RAIR-DTC中的检出率均低于2-[18F]FDG PET/CT(60.00% vs. 90.00%,P = .004;59.38% vs. 96.88%)。免疫组化显示RAIR-DTC的PSMA表达显著高于DTC,但PSMA表达与[68Ga]Ga-PSMA-11 PET/CT的SUVmax无显著相关性。
要点
- [68Ga]Ga-PSMA-11 PET/CT对甲状腺癌转移灶的检出率低于2-[18F]FDG PET/CT。
- RAIR-DTC的2-[18F]FDG PET/CT半定量参数高于DTC,而[68Ga]Ga-PSMA-11 PET/CT参数两者无显著差异。
- RAIR-DTC的PSMA表达显著高于DTC,但未反映在[68Ga]Ga-PSMA-11 PET/CT上。
核心结论
- [68Ga]Ga-PSMA-11 PET/CT能检测甲状腺癌转移灶,但检出率低于2-[18F]FDG PET/CT;DTC与RAIR-DTC的PSMA表达水平存在差异,但该差异未反映在[68Ga]Ga-PSMA-11 PET/CT上。
研究设计与样本
- 前瞻性头对头比较研究,纳入23例DTC和17例RAIR-DTC患者,所有患者均行[68Ga]Ga-PSMA-11 PET/CT和2-[18F]FDG PET/CT,并对12例淋巴结转移灶组织标本行PSMA免疫组化。
关键影像表现/征象
- 共检出72个病灶。
- RAIR-DTC的2-[18F]FDG PET/CT半定量参数高于DTC。
- DTC与RAIR-DTC的[68Ga]Ga-PSMA-11 PET/CT半定量参数无显著差异。
- 免疫组化显示RAIR-DTC的PSMA表达显著高于DTC。
- PSMA表达与[68Ga]Ga-PSMA-11 PET/CT的SUVmax无显著相关性。
诊断标准与关键数值
- DTC检出率:[68Ga]Ga-PSMA-11 PET/CT 60.00% vs. 2-[18F]FDG PET/CT 90.00%,P = .004。
- RAIR-DTC检出率:[68Ga]Ga-PSMA-11 PET/CT 59.38% vs. 2-[18F]FDG PET/CT 96.88%。
临床应用与阅片要点
- 原文结论指出[68Ga]Ga-PSMA-11 PET/CT在甲状腺癌诊断中具有潜在价值。
- 原文结论指出[68Ga]Ga-PSMA-11 PET/CT可筛选出可能受益于PSMA靶向放射性核素治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Thyroid cancer is increasing in incidence. Prostate-specific membrane antigen (PSMA) targeted radionuclide imaging and treatment demonstrated remarkable value in prostate cancer patients. Studies have shown that PSMA is also expressed in thyroid cancer. Our purpose is to evaluate the clinical usefulness of [68Ga]Ga-PSMA-11 PET/CT for the diagnosis of thyroid cancer.
METHODS: We enrolled 23 DTC and 17 RAIR-DTC patients prospectively. All patients underwent [68Ga]Ga-PSMA-11 PET/CT and 2-[18F]FDG PET/CT. PSMA expression was determined by immunohistochemistry on histological samples of lymphatic metastasis of 12 patients. We compared the detection rates and semi-quantitative parameters between [68Ga]Ga-PSMA-11PET/CT and 2-[18F]FDG PET/CT.
RESULTS: A total of 72 lesions were detected. Detection rates of DTC and RAIR-DTC by [68Ga]Ga-PSMA-11 PET/CT were lower than those by 2-[18F]FDG PET/CT (60.00% vs. 90.00%, P = .004; 59.38% vs. 96.88%). Compared with DTC, RAIR-DTC had higher semi-quantitative parameters of 2-[18F]FDG PET/CT. There was no significant difference in semi-quantitative parameters of [68Ga]Ga-PSMA-11 PET/CT between DTC and RAIR-DTC. Immunohistochemistry showed a significantly higher PSMA expression for RAIR-DTC than for DTC. However, there was no significant correlation between PSMA expression and SUVmax on 68Ga-PSMA [68Ga]Ga-PSMA-11 PET/CT.
CONCLUSIONS: [68Ga]Ga-PSMA-11 PET/CT can detect thyroid cancer metastases but its detection rate was lower than that of 2-[18F]FDG PET/CT. There was a difference in PSMA expression levels between DTC and RAIR-DTC, but the difference was not reflected on [68Ga]Ga-PSMA-11 PET/CT.
ADVANCES IN KNOWLEDGE: [68Ga]Ga-PSMA-11 PET/CT has potential value in the diagnosis of thyroid cancer. [68Ga]Ga-PSMA-11 PET/CT could screen out patients who may benefit from PSMA-targeted radionuclide therapy.
引用
- Shi Y, Feng Y, Xu L, et al. The value of gallium-68 prostate-specific membrane antigen PET/CT and 2-[18F]fluoro-2-deoxy-D-glucose PET/CT in the detection of thyroid cancer lesions: a prospective head-to-head comparison. Br J Radiol. 2023. PMID: 38904463. doi:10.1259/bjr.20230291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。